Recommendations to improve using Overall Survival data to inform benefit-risk assessments – FDA Oncology
FDA Oncology posted on X about recent paper by Lisa Rodriguez et al., commenting:
“In a new Clinical Cancer Research paper, FDA’s Lisa Rodriguez, Nicole Gormley and colleagues share best practices, propose novel statistical methodologies, and provide recommendations to improve the rigor of using Overall Survival data to inform benefit-risk assessments.”
Improving Collection and Analysis of Overall Survival Data
Journal: AACR Journals
Author: Lisa R. Rodriguez, Nicole J. Gormley, Ruixiao Lu, Anup K. Amatya, George D. Demetri, Keith T. Flaherty, Ruben A. Mesa, Richard Pazdur, Mikkael A. Sekeres, Minghua Shan, Steven Snapinn, Marc R. Theoret, Rukiya Umoja, Jonathon Vallejo, Nicholas J. H. Warren, Qing Xu, Kenneth C. Anderson
Source: FDA Oncology/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023